Fri, March 1, 2024
Thu, February 29, 2024
Wed, February 28, 2024

David Hoang Maintained (SRPT) at Strong Buy with Increased Target to $172 on, Feb 29th, 2024


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-172-on-feb-29th-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

David Hoang of Citigroup, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $160 to $172 on, Feb 29th, 2024.

David has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Hold with Increased Target to $138 on, Tuesday, February 20th, 2024


These are the ratings of the 6 analyists that currently disagree with David


  • Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $224 on, Tuesday, February 20th, 2024
  • Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $145 on, Wednesday, February 14th, 2024
  • Kostas Biliouris of "BMO Capital" Initiated at Buy and Held Target at $170 on, Wednesday, January 31st, 2024
  • Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $109 on, Tuesday, December 12th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023

Publication Contributing Sources